Back

Loss of DAXX induces alternative lengthening of telomeres (ALT)-associated hallmarks in prostate cancer cells in a context-specific manner

Mori, J. O.; Da, J.; Kim, J.; Rizzo, A.; Davis, C.; Lanza, C.; Brosnan-Cashman, J. A.; Meeker, A. K.; Heaphy, C. M.; Graham, M. K.

2025-08-09 cancer biology
10.1101/2025.08.06.668744 bioRxiv
Show abstract

BackgroundThe histone chaperone complex, consisting of the death domain-associated protein (DAXX) and the alpha-thalassemia/mental retardation X-linked protein (ATRX), plays a pivotal role in maintaining chromatin through the deposition of the histone variant H3.3. Mutations leading to loss of ATRX or DAXX function are linked to the non-telomerase, alternative lengthening of telomeres (ALT) phenotype in certain cancers. Engineered ATRX mutations have previously been found to induce features of ALT in prostate cancer cell lines, notably in LAPC-4, but not in CWR22Rv1. This study determined the impact of DAXX mutations on ALT-associated characteristics in CWR22Rv1 and LAPC-4. MethodologyMutations were induced in CWR22Rv1 and LAPC-4 cells by targeting exon 2 of DAXX using the CRISPR-Cas9 genome editing strategy. The resulting mutant clones were then evaluated for ALT-associated characteristics, including the presence of ALT-associated PML bodies (APBs), C-circles, telomere length heterogeneity, and a lack of telomerase activity. ResultsFour CWR22Rv1 DAXX mutant clones (DAXXMut1-4) and five LAPC-4 clones (DAXXMut1-5) were evaluated. In CWR22Rv1, DAXXMut1, DAXXMut2, and DAXXMut4 were true knockout clones with frameshift mutations in both copies, while CWR22Rv1 DAXXMut3 had a frameshift mutation in one copy and an in-frame mutation in the other. Protein expression was undetectable in all the CWR22Rv1 clones, including CWR22Rv1 DAXXMut3. In LAPC-4, DAXXMut1 was a true knockout, while DAXXMut2, DAXXMut3, DAXXMut4, and DAXXMut5 clones had at least one in-frame mutation. Among these LAPC-4 clones, only DAXXMut1 had undetectable protein by western blotting. ALT-associated characteristics such as APBs, C-circles, and telomere length heterogeneity were observed only in CWR22Rv1 DAXXMut4. All the clones maintained telomerase activity, regardless of whether ALT-associated hallmarks were observed. ImplicationsThe CWR22Rv1 and LAPC-4 DAXX mutant clone models provide useful tools for future studies on telomere maintenance mechanisms and DAXX-related biology, particularly in prostate cancer.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
International Journal of Cancer
42 papers in training set
Top 0.1%
14.4%
2
The Prostate
11 papers in training set
Top 0.1%
14.4%
3
PLOS ONE
4510 papers in training set
Top 25%
6.9%
4
Clinical Epigenetics
53 papers in training set
Top 0.2%
4.9%
5
Scientific Reports
3102 papers in training set
Top 27%
4.3%
6
Molecular Oncology
50 papers in training set
Top 0.1%
4.0%
7
Frontiers in Oncology
95 papers in training set
Top 1%
3.6%
50% of probability mass above
8
Molecular Cancer Research
42 papers in training set
Top 0.1%
3.3%
9
Cancers
200 papers in training set
Top 2%
3.1%
10
BMC Cancer
52 papers in training set
Top 0.9%
2.6%
11
Aging
69 papers in training set
Top 0.9%
2.6%
12
Journal of Translational Medicine
46 papers in training set
Top 0.4%
2.4%
13
Cancer Research Communications
46 papers in training set
Top 0.4%
1.7%
14
Cells
232 papers in training set
Top 3%
1.7%
15
Molecular Cancer Therapeutics
33 papers in training set
Top 0.4%
1.7%
16
Clinical Cancer Research
58 papers in training set
Top 1%
1.5%
17
Oncotarget
15 papers in training set
Top 0.2%
1.2%
18
Nature Communications
4913 papers in training set
Top 61%
0.8%
19
Cancer Medicine
24 papers in training set
Top 1%
0.8%
20
Neuro-Oncology
30 papers in training set
Top 0.7%
0.8%
21
Cancer Epidemiology, Biomarkers & Prevention
17 papers in training set
Top 0.6%
0.8%
22
British Journal of Cancer
42 papers in training set
Top 1%
0.8%
23
Medicine & Science in Sports & Exercise
15 papers in training set
Top 0.5%
0.8%
24
Human Molecular Genetics
130 papers in training set
Top 4%
0.6%
25
Cancer Research
116 papers in training set
Top 4%
0.6%
26
The Journals of Gerontology: Series A
25 papers in training set
Top 1.0%
0.6%
27
Genetics
225 papers in training set
Top 5%
0.5%